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Predicting the dispositional kinetics of
xenobiotics in humans from data acquired
in animals is an important enterprise.
Predicted pharmacokinetic parameters have
application in drug development such as in
the prediction of initial doses of investiga-
tional new drugs for human studies.
Predicted toxicokinetic parameters have
applications in toxicology such as in the
prediction of the time course of exposure
after acute or chronic challenge with toxic
substances. Knowledge of the time course
may be helpful in predicting both the
aggressiveness of treatments and the dura-
tion of such treatments. Another applica-
tion is in carcinogenic risk assessment.
Estimates of toxicokinetic parameters in
humans for individual xenobiotics may be
attained either through interspecies allomet-
ric scaling (1,2) or through physiologically
based pharmacokinetic (PBPK) modeling
(3), which ultimately must invoke an inter-
species scale-up as well, at least for data
elicited exclusively from an animal model
(4). In allometric scaling, kinetic variables
such as volume of distribution and half-life
are scaled based on the assumption that they
are proportional to a power ofbody weight,
and xenobiotic clearance is additionally fac-
tored bythe species' life span (5).
Interspecies scaling as it relates to
dosimetry centers on adjustments based on
species mass (i.e., body weight), though
some prefer that adjustments from one
species to another take account ofbody sur-
face area rather than body weight. For
example, the U.S. Environmental Pro-
tection Agency suggests that doses be scaled
from rats to humans on the basis of the
ratio of human body weight to rat body
weight (BW) raised to the 0.667 power, as
follows (6):
Dosehuman = Doserat (BWhuma*/BWrat)0667 (1)
Recent proposals suggest that the exponent
used should be 0.75 (7) rather than 0.667,
and this value appears to be justifiable on
the basis that basal metabolic rate is a func-
tion of mass raised to the 0.75 power as
shown (8):
Basal metabolism = aM075 (2)
where a is a mass coefficient set at 70 kcal
and Mis mass in kilograms. Related para-
meters that scale to BW0_75 include alveo-
lar ventilation, cardiac output, renal clear-
ance, and oxygen consumption (9). Most
often, the allometric scaling ofkinetic vari-
ables is undertaken on a case-by-case basis
(i.e., xenobiotic by xenobiotic), with kinet-
ic parameters for individual xenobiotics
evaluated in each ofmultiple species (10).
We were interested in determining
whether reasonable predictions of two
kinetic parameters of xenobiotics, volume
of distribution and half-life, could be
made for humans ifone had knowledge of
those parameters from rat data only. Our
working hypothesis was that a useful pre-
dictive mathematical relationship was like-
ly to exist if one regressed known human
toxicokinetic variable estimates (volume of
distribution and half-life) against known
data for the same variables in rats, and did
so across a large series ofxenobiotics. Such a
relationship would establish a single model
from which volume of distribution and
half-life for any xenobiotic could be pre-
dicted for humans and, further, could be
predicted entirely from the estimates of
those variables in rats.
Methods
Average values for rats and humans for vol-
umes ofdistribution of 100 xenobiotics and
for half-lives of 103 xenobiotics were
obtained from the literature. Most of the
xenobiotics were "drugs" insofar as there is
a substantially larger literature for human
pharmacokinetic parameters than toxicoki-
netic parameters. A table denoting each
xenobiotic, the average toxicokinetic or
pharmacokinetic parameters for both rats
and humans and the source ofthe data are
given in the appendix.
We modeled half-life andvolume ofdis-
tribution data using the statistical computa-
tion program, S-Plus (Mathsoft Inc.,
Seattle, Washington), which provided con-
fidence limits for model predictions. The
program ran on a SPARCserver 10 comput-
er. Our aim was to find a simple yet effec-
tive model describing the human data as a
function of that of the rat. Further, it was
important to identify confidence limits on
predictions that may arise from such a
model. Noting how the variability in each
data set increases linearlywith the values for
the rat for each parameter we decided to
explore logarithmic models because these
models are inherently multiplicative in the
error terms, as will be seen below.
Results
After confirming that quadratic terms were
not statistically significant, and upon noting
that the logarithmic transformations yielded
a standard deviation for human values that
was constant across ratvalues (see Figs. 1 and
2), a linear model that is logarithmic in both
variables was selected for both data sets:
log(Pum ) = a + [bxlog(P,ra)] + e,
i= 1,2,...,n (3)
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where P denotes the kinetic parameter
(half-life or volume ofdistribution) and the
errors, e1, are assumed to be normally dis-
tributed with a constant standard devia-
tion, (T. This model can be rewritten in
more familiar terms as:
P =axPb 'human i irat (4)
where ai depends on both the parameter cc
and the individual errors, e,. Thus, the vari-
ability ofthe actual human parameter value
is proportional to the rat value raised to the
power b.
Results of the regression analysis from
S-Plus are given in Table 1. Included are
the parameter estimates along with their
standard errors for each data set. All the
parameters are significant with p-values
based on the t-distribution <0.0001. The
X2 values are 0.737 and 0.754 for half-life
and volume ofdistribution analyses, respec-
tively, demonstrating a reasonably good fit
in both cases. The estimated regression
curves, or prediction lines, for half-life and
volume ofdistribution are shown in Figures
1 and 2, respectively. The exponents (b) are
0.83 for half-life and 0.91 for volume of
distribution, respectively. Also given in
these figures are the 80%, 90%, and 95%
prediction intervals for a new human value
corresponding to the given rat value. These
curves take into account the possible errors
in the prediction line itself (in the estimat-
ed a and b) and the error inherent to a new
observation (as quantified by the regression
estimate of a).
The validity ofthe regression equations
was confirmed as follows: for the half-life
data, the regression equation along with
the prediction intervals was computed
using a subset of the data originally
obtained (i.e., all but 18 ofthe data points
ultimately used). The additional 18 data
points (these are marked with footnote a in
the data listings in the appendix) obtained
later were compared to the regression
results with these points excluded. These
points followed basically the same pattern
as the larger data set. Furthermore, two of
these points fell outside the 80% predic-
tion intervals (about three or four would
have been expected to do so); none ofthese
points fell outside the 90% prediction
intervals (one or two would have been pre-
dicted to do so); and none fell outside the
95% prediction intervals (one or fewer
would be expected). As the regression rela-
tionship thus proved to be useful in pre-
dicting human half-lives from rat half-lives,
we concluded that the regression results
obtained were valid. Note that the regres-
sion results in the tables and figures employ
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Figure 1. Human half-lives for 103 xenobiotics plotted against rat half-lives. Half-lives are given in hours.
Both axes are logarithmically scaled.
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Table 1. Regression analysis for human versus rat parameters
Estimate SE t p Residual SE Multiple R2
Half-life
Intercept (a) 1.58 0.083 19.09 0.0000
Slope (b) 0.83 0.041 16.83 0.0000
0.835 0.737
Volume
Intercept (a) -0.35 0.077 -4.6 0.0000
Slope (b) 0.91 0.052 17.3 0.0000
0.766 0.754
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the full data set [i.e., the data include both
the original and expanded (additional 18
observations) half-life data].
The prediction intervals in Figures 1
and 2 are supplemented by Tables 2 and 3,
which present the intervals for awide range
ofrat values in numerical form.
To illustrate the use and interpretation
ofthe information contained in these tables,
consider a newly encountered substance, X,
whose human half-life we desire to ascertain.
Say that from a toxicokinetic study in rats, X
is estimated to exhibit a half-life of 0.8 hr.
Table 2 provides the following information
about the prediction ofthe human half-life.
First, the prediction, or best guess of the
human half-life is 4.02 hr. If, for example,
we desired to have an interval in which we
were 90% confident that the human half-
life would lie, Table 3 indicates that
1.0-16.2 hr is the interval. That is, based on
the results ofthis regression analysis, we can
be 90% certain that the human half-life for
Xis between 1.0 and 16.2 hr. If interpola-
tion is required, the table is constructed in
such a way that linear interpolation should
be adequate. For instance, ifthe rat half-life
had been estimated to be 2.7 hr instead of
0.8, then interpolating linearly between the
predicted human values of 8.60 (for a rat
half-life of2 hr) and 12.04 (for a rat half-life
of 3 hr), the prediction for human half-life
would be 11.01 hr.
Discussion
In contrast to customary scaling studies, we
wanted to determine whether a model
could be developed for predicting the toxi-
cokinetic or pharmacokinetic parameters of
any xenobiotic in humans based expressly
on the availability of estimates of those
parameters in rats. To do so we regressed
Phuman against brat for over 100 xenobi-





which, employing the logarithmic transfor-
mation, accounts for over 75% ofthe vari-
ance in the relationship between Phuman and
Prat' This is particularlystriking for avariety
of reasons, including, though not limited
to, the following: 1) multiple strains of rats
were used in assimilating the data sets; 2)
some of the data were acquired from male
rats and some from female rats; 3) it was
assumed, though not necessarily demon-
strated, that elimination kinetics in all cases
was first order. In fact, some ofthe xenobi-
otics exhibited clear dose-dependent kinet-
ics in rats, and when such was the case the
kinetic parameters were selected from the



































































































































































































lowest dose tested; 4) the sizes and ages of
rats used were not uniform; 5) there was
insufficient technical detail (e.g., sampling
times, duration of sampling, number of
subjects) to determine whether all studies
from which kinetic datawere gathered were
structured appropriately (i.e., the goodness
ofthe underlying data cannot be validated);
6) data for each xenobiotic were published
generally without regard to chirality consid-
erations; 7) data from a single experiment
in a single sample ofsubjects were taken to
be representative; 8) dataforhumans gener-
ally did not take account of sex; 9) no
accommodation was made for the differ-
ences in protein-binding between species;




































































































































































































11) elimination pathways were not identical
for all xenobiotics in both species; and 12)
when explicit weights were not provided,
rat weights were set at 0.25 kg and human
weights at 70 kg.
Inspection ofTables 2 and 3 shows that
the 80% confidence limits for each predict-
ed human parameter embrace an approxi-
mate 10-fold range of values. The full
range ofvalues for a given parameter for a
given xenobiotic when estimated directly
even from a single small sample ofhumans
may also extend an order ofmagnitude or
more. It is possible that the range of pre-
dicted values could have been tightened,
and the scatter of data around the predic-
tion line could have been diminished if
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data sets had been developed prospectively
rather than retrospectively and attention
had been paid to the itemized points above.
The sine qua non for risk assessment
purposes appears to be PBPK modeling,
which mathematically describes uptake,
























































































































































chemicals for physiologically relevant tissue
compartments (11,12). However, 24 or
more physiological, physicochemical, and
enzyme kinetic parameters must be known
for a given xenobiotic in a given animal
model in order for PBPK models to accu-
rately simulate the time course of xenobi-
otics in tissue compartments. Those active
in the field point to the difficulty and
expense associated with the development of
comprehensive models (12).
The simple model presented here
allows for the prediction of body burdens
ofxenobiotics during chronic exposure if
the exposure rate is known:
As= E(1.44 xtl2) (6)
whereASS is the average amount ofxenobi-
otic in the body at steady-state and Eis the
exposure rate (the fraction ofdose absorbed
during each exposure period). Alter-
natively, exposure rates can be estimated
from measurement of an average steady-
state plasma concentration:
E= FD/t = C (V/1.44) x t112 (7)
where D is the dose, Fis the fraction ofthe
dose absorbed, Vis the volume ofdistribu-
tion, X is the interval of exposure, and Css
is the measured average steady-state con-
centration ofthe xenobiotic. To the extent
that toxicity or carcinogenicity is a func-
tion of reactive metabolites, additional
information would be required such as tar-
get tissue burdens of such metabolites at
steady state. We do not propose that the
simple model developed in this paper
ought to supplant other strategies incorpo-
rated into risk assessment models, be used
to predict initial doses of xenobiotics in
humans, or be used to gauge the duration
of exposures to xenobiotic challenges.
Nevertheless, in an era of cost conscious-
ness, it may be useful to apply simple
strategies for such purposes when circum-
stances permit, and it may be instructive to
ascertain those circumstances in which sim-
ple models may be as usefully informative
as far more complex ones.
Appendix
Tabulation ofKinetic Parameters in Rats and Humans for 120 Xenobiotics
Volume ofdistribution (I/kg)
Xenobiotic Rat Ref. Human Ref.
ALO 1567 0.45 (13) 0.77 (13)
ALO 1576 0.97 (13) 2.40 (13)
3TC8
Aspirin 0.37 (14) 0.15 (15)
AZT8 2.12 (16) 1.40 (16)
CSFa
FCE 22101 0.05 (17) 0.24 (17)
L-DOPA 9.8 (18) 1.65 (19)
PCP (phency- 23.2 (20) 6.20 (20)
clidine)
MK476a
Acetaminophen 1.02 (21) 0.95 (15)
Acivicin 0.65 (22) 0.50 (15)
Acyclovir 0.7 (23) 0.69 (15)
Half-life (hr)
Rat Ref. Human Ref. Xenobiotic
15.59 (13) 63 (13) Alteplase
33.61 (13) 72 (13) Amiodarone
1.6 (117) 2.6 (117) Amitriptyline
0.07 (14) 0.29 (15) Amobarbital
0.39 (16) 1.35 (16) Amoxicillin
1.1 (118) 3.5 (119) Amphotericin B
0.09 (17) 0.74 (17) Antipyrine
Aprobarbital
2.2 (20) 16 (20) Atenolol
Baclofen
1.4 (120) 3.8 (120) Betamipron
0.27 (107) 2 (15) Hl-6a
1.44 (22) 9.5 (22) Brodifacouma
1.39 (23) 2.4 (108) Caffeine
Volume ofdistribution (I/kg) Half-life (hr)
Rat Ref. Human Ref. Rat Ref. Human Ref.
0.08 (24) 0.05 (15) 0.04 (109) 0.07 (109)
72.3 (25) 66 (15)
15.83 (26) 15 (15) 1.47 (26) 15.06 (15)
1.46 (27) 1.01 (27) 1.73 (27) 22.7 (27)
0.42 (28) 0.21 (15) 0.3 (28) 1.7 (15)
3.46 (29) 3.37 (15) 10.2 (29) 86 (125)
0.92 (30) 0.56 (31) 1.48 (28) 12 (110)
5.79 (99) 24 (119)
3.41 (32) 0.95 (15)
1.19 (33) 0.48 (34)
0.24 (35) 0.28 (35) 0.16 (35) 0.81 (35)
0.39 (121) 1.42 (121)
156 (123) 576 (122)
0.92 (36) 0.61 (15) 0.85 (36) 4.9 (15)
appendixcontinued
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appendix, continued
Volume of distribution (I/kg) Half-life (hr) Volume of distribution(I/kg) Half-life (hr)
Xenobiotic Rat Ref. Human Ref. Rat Ref. Human Ref. Xenobiotic Rat Ref. Human Ref. Rat Ref. Human Ref.
Carbamazepine 12.91 (37) 1.4 (15) Lithiuma 6.1 (135) 28.9 (135)
Cefadroxil 0.79 (38) 0.22 (15) 0.82 (38) 1.1 (15) Meberinea 0.48 (136) 2.5 (136)
Cefazolin 0.22 (39) 0.12 (15) 0.39 (39) 1.8 (15) Methadone 7.81 (82) 4.24 (15) 1.45 (82) 35 (15)
Cefmetazole 0.49 (39) 0.14 (39) 0.14 (39) 1.55 (39) Methotrexate 0.96 (51) 0.55 (15) 2.66 (51) 8.4 (51)
Cefodizime 0.18 (40) 0.19 (41) 1.82 (40) 1.6 (41) Methylmercurya 1776 (137) 1056 (138)
Cefoperazone 0.29 (39) 0.09 (15) 0.15 (39) 2.1 (15) Methysergide 1.43 (80) 0.93 (81) 0.02 (80) 0.75 (81)
Cefotetan 0.25 (39) 0.13 (15) 0.22 (39) 2.57 (15) Metoclopramide 1.13 (83) 2.68 (15) 0.33 (83) 5 (15)
Cefpiramide 0.26 (39) 0.11 (39) 0.32 (39) 5.41 (39) Metoprolol 6.72 (32) 4.16 (15) 0.66 (115) 3.2 (15)
Cefpirome 0.57 (42) 0.31 (43) Midazolam 1.64 (84) 1.1 (15) 0.28 (84) 1.9 (15)
Ceftizoxime 0.44 (44) 0.36 (15) 0.26 (44) 1.8 (15) Mitomycin Ca 0.47 (139) 0.67 (139)
Cephradine 0.43 (45) 0.25 (15) 0.81 (45) 0.77 (15) Morphine 2.87 (85) 3.3 (15) 0.46 (116) 1.9 (15)
Chlorpromazine 29.1 (46) 11.2 (46) 5.55 (46) 30 (15) Moxalactam 0.28 (39) 0.25 (15) 0.34 (39) 2.1 (15)
Cimetidine 1.36 (47) 1.0 (15) 0.4 (111) 2 (15) Nicardipine 1.28 (86) 1.1 (15) 0.13 (86) 1.3 (15)
Cisplatin 2.06 (48) 0.28 (15) 0.79 (48) 0.53 (15) Nicotine 5.70 (87) 2.6 (15) 1.16 (87) 2 (15)
Clavulanic acid 0.44 (49) 0.21 (15) Ofloxacin 1.54 (88) 2.95 (89)
Cocaine 17.2 (50) 2.0 (15) 0.85 (50) 0.8 (15) Oxazepama 4.5 (140) 6.8 (15)
Codeine 3.6 (50) 2.6 (15) 0.55 (124) 2.9 (15) Panipenem 0.19 (35) 0.18 (35)
Cyclophosphamide0.9 (51) 0.78 (15) 2.49 (51) 5.25 (51) Pentamidinea 0.03 (141) 0.28 (141)
Cyclosporine 4.54 (52) 1.2 (15) 15.51 (52) 16 (52) Pentazocine 7.66 (90) 7.1 (15) 1.13 (90) 4.6 (15)
Diazepam 5.3 (53) 1.1 (15) 1.42 (53) 43 (15) Pentobarbital 1.64 (27) 0.99 (27) 2.26 (27) 22.3 (27)
Dideoxycytidine 0.98 (126) 1.2 (127) Phenobarbital 1.02 (27) 0.54 (15) 6.32 (27) 99 (15)
Diflunisal 0.13 (54) 0.10 (15) 1 (54) 11.55 (15) Phenprocoumona 17.4 (142) 128 (143)
Digoxin 3.48 (55) 9.19 (15) 2.5 (55) 39 (15) Phenylbutazone 0.24 (27) 0.10 (15) 4.17 (27) 56 (15)
Enprofylline 0.34 (56) 0.51 (56) 0.27 (56) 1.42 (128) Physostigmine 0.25 (144) 0.42 (145)
Erythropoietina 0.07 (57) 0.03 (58) 2.64 (57) 5 (58) Piroxicam 1.94 (91) 0.15 (15) 8.4 (91) 48 (91)
Ethanol 0.61 (59) 0.54 (15) Panipenem 0.08 (35) 0.84 (35)
Ethosuximide 0.70 (60) 0.72 (15) 5.5 (129) 33 (130) Prednisolone 1.74 (92) 1.5 (15) 0.2 (93) 2.2 (15)
Ethoxyacetic acida 7.2 (131) 42 (131) Prednisone 1.3 (93) 0.97 (15) 0.1 (93) 3.11 (15)
Etretinate 1.33 (61) 1.50 (62) Procainamide 3.72 (94) 1.9 (15) 0.69 (94) 3 (15)
Famotidine 1.65 (63) 1.15 (15) 0.44 (63) 2.83 (63) Propafenone 5.2 (95) 3.88 (95) 0.97 (95) 6.5 (95)
Felbamate 0.42 (64) 0.85 (65) 2.78 (64) 13.3 (64) Propranolol 5.3 (96) 4.3 (15) 0.72 (96) 2.78 (96)
Fentanyl 11.2 (66) 7.7 (112) 1.93 (112) 7.9 (112) Pyrimethamine 1.14 (97) 2.9 (15)
Fluconazolea 4 (132) 26.4 (132) Quinidine 6.0 (98) 2.7 (15) 2.05 (98) 6.2 (15)
Fluoxetine 15.9 (67) 35 (15) 3.92 (67) 42.1 (15) Secobarbital 0.97 (99) 1.5 (100) 0.89 (99) 26.5 (100)
Flurbiprofen 0.36 (68) 0.21 (69) Sertraline 23 (101) 25 (102) 4.5 (101) 24 (102)
Gabapentina 2 (133) 5.5 (133) Sulfadiazine 0.39 (103) 0.29 (15) 3.86 (103) 9.9 (15)
Gentamicin 0.6 (70) 0.31 (15) Sulfizoxazole 0.32 (103) 0.15 (15) 4.44 (103) 6.6 (15)
Hexobarbital 0.7 (27) 1.2 (15) 0.42 (134) 4.4 (134) Theophyllinea 0.50 (79) 0.50 (15) 2 (146) 7.3 (146)
Ibuprofen 0.55 (71) 0.15 (15) 1.31 (71) 2 (15) Ticarcillin 0.25 (49) 0.21 (15) 0.22 (49) 1.21 (15)
Imipramine 17.48 (72) 23 (72) 3.42 (113) 18 (15) Tolbutamide 0.22 (27) 0.10 (15) 1.82 (27) 7.2 (27)
Indomethacin 0.12 (73) 0.26 (15) 2.77 (114) 2.4 (15) Tolmetin 0.18 (104) 0.54 (15)
Isoniazid 0.63 (74) 0.67 (15) 0.74 (74) 3.1 (15) Trimethoprim 2.47 (105) 1.8 (15) 0.61 (105) 11 (15)
Isotretinoin 1.8 (75) 7 (15) Valproate 0.66 (27) 0.13 (27) 4.6 (27) 14 (15)
Ketoconazole 0.66 (76) 2.4 (15) 0.53 (76) 3.3 (15) Vancomycin 1.02 (106) 0.39 (15) 1.44 (106) 5.6 (15)
Ketoprofen 0.37 (77) 0.15 (15) Verapamil 1.6 (147) 4 (15)
Ketorolac 0.38 (78) 0.11 (78) 1.8 (78) 6.5 (78) Warfarin 0.20 (27) 0.14 (15) 11.1b (27,148) 37 (15)
Lidocaine 2.52 (79) 1.1 (15) 0.62 (79) 1.38 (15)
aDenotes subset ofxenobiotics tested against model that had been developed withoutthe subset(see Results).
bUnweighted average of mean values reported in Sawada et al. (27) and Takada and Levy(148).
REFERENCES
1. Boxenbaum H, Ronfeld R. Interspecies phar-
macokinetic scaling and the Dedrick plots. Am
J Physiol 245:R768-R775 (1983).
2. Boxenbaum H. Interspecies pharmacokinetic
scaling and the evolutionary-comparative para-
digm. Drug Metab Rev 15:1071-1121 (1984).
3. Gerlowski L, Jain R. Physiologically based
pharmacokinetic modeling:principles and
applications. J Pharm Sci 72:1103-1126
(1983).
4. Sawada Y, Harashima H, Hanano M,
Sugiyama Y, Iga T. Prediction of the plasma
concentration time courses ofvarious drugs in
humans based on data from rats. J
Pharmacobio-Dyn 8:757-766 (1985).
5. Boxenbaum H. Interspecies scaling, allometry,
physiological time, and the ground plan of
pharmacokinetics. J Pharmacokinet Biopharm
10:201-227 (1982).
6. Fan A, Howd R, Davis B. Risk assessment of
environmental chemicals. Annual Reviews of
Pharmacol Toxicol 35:341-368 (1995).
7. Travis C, White R Interspecies scaling oftoxi-
city data. RiskAnal 8:119-125 (1988).
8. Sidhu K. Basis for body weight exponent
(0.75) as a scaling factor in energy metabolism
and risk assessment. J Appl Toxicol
12:309-310 (1992).
9. Travis C, White R, Ward, R. Interspecies
extrapolation of pharmacokinetics. J Theor
Biol 142:285-304 (1990).
10. Boxenbaum H, Fertig J. Scaling of antipyrine
intrinsic clearance of unbound drug in 15
mammalian species. Eur J Drug Metab
Pharmacokinet 9:177-183 (1984).
11. Andersen ME, Krishnan K, Conolly R,
McClellan R. Biologically based modeling in
toxicology research. Arch Toxicol 15:217-227
(1992).
12. Krewski D, Withey J, Ku L, Andersen ME.
Applications of physiologic pharmacokinetic
modeling in carcinogenic risk assessment.
Environ Health PerspectlO2(suppl 11):37-50
(1994).
13. Brazzell R, Park T, Wooldridge C, McCue B,
Barker R, Couch R, Yark B. Interspecies com-
parison of the pharmacokinetics of aldose
reductase inhibitors. Drug Metab Dispos 18:
435-440 (1990).
14. Wientjes MG, Levy G. Nonlinear pharmacoki-
404 Volume 104, Number4, April 1996 * Environmental Health PerspectivesArticles * Scaling basic toxicokinetic parameters
netics ofaspirin in rats. J Pharmacol Exp Ther
245:809-815 (1988).
15. Benet L, Williams R Design and optimization
of dosage regimens. In: The pharmacological
basis of therapeutics, 8th ed (Goodman
Gilman A, Rall T, Nies A, Taylor P, eds). New
York:Pergamon Press, 1990;1650-1735.
16. Patel B, Boudinot D, Schinazi R, Galb J, Chu
C. Comparative pharmacokinetics and inter-
species scaling of 3'-azido-3'-deoxythmidine
(AZT) in several mammalian species. J
Pharmacobio-Dyn 13:206-211 (1990).
17. Efthymiopoulos C, Battaglia R, Strolin MB.
Animal pharmacokinetics and interspecies scal-
ing of FCE 22101, a penem antibiotic. J
Antimicrob Chemother 27:517-526 (1991).
18. Rose S, Jenner P, Marsder C. Peripheral phar-
macokinetics handling and metabolism of L-
dopa in the rat:the effect of route of adminis-
tration and cardidopa pretreatment. J Pharm
Pharmacol 43:325-330 (1991).
19. Robertson DR, Wood ND, Everest H, Monks
K, Waller DG, Renwick A, George CF. The
effect of age on the pharmacokinetics of lev-
odopa administered alone and in the presence
of carbidopa. Br J Clin Pharmacol 28:61-69
(1989).
20. Owens S, Hardwick W, Blackall D.
Phencyclidine pharmacokinetic scaling among
species. J Pharmacol Exp Ther 242:96-101
(1987).
21. Belanger P, Lalande M, Dore F, Labricque G.
Time-dependent variations in the organ extrac-
tion ratios of acetaminophen in rat. J
Pharmacokinet Biopharm 15:133-141 (1987).
22. McGovern J, Williams M, Stewart J.
Interspecies comparison of acivicin pharmaco-
kinetics. Drug Metab Dispos 16:18-22
(1988).
23. Fujioka Y, Mizuno N, Morita E, Motozono H,
Takahashi K, Yamanaka Y, Shinkuma D.
Effect ofage on the gastrointestinal absorption
of acyclovir in rats. J Pharm Pharmacol
43:465-469 (1991).
24. Hori R, Ite Y, Shima T, Invi K, Aoki S,
Okumura K, Tanigawara Y. Total body and
hepatic clearance in rats of recombinant tissue
type plasminogen activator expressed in mouse
C127 and chinese hamster ovary cells. Drug
Metab Dispos 20:541-546 (1992).
25. Wyss P, MoorJ, Bickel M. Single-dose kinetics
of tissue distribution, excretion and metabo-
lism of amiodarone in rats. J Pharmacol Exp
Ther254:502-504 (1990).
26. Miyake K, Fukuchi H, Kitaura T, Kimura M,
Kimura Y. Pharmacokinetic analysis of
amitriptyline and demethylated metabolite in
serum and brain ofrats after acute and chronic
oral administration of amitriptyline. J
Pharmacobio-Dyn 15:157-166 (1992).
27. Sawada Y, Hanano M, Sugiyama Y, Iga T.
Prediction of the disposition of nine weakly
acidic and six weakly basic drugs in humans
from pharmacokinetcs in rats. J Pharmacokinet
Biopharm 13:477-492 (1985).
28. Torres-Molina F, Aristorena J. Garcia-
Carbonell, Granero L, Chese-Jimenez J, Pla-
Delfina J, Peris-Ribeno J. Influence of perma-
nent cannulation of the jugular vein on phar-
macokinetics ofamoxycillin and antipyrine in
the rat. Pharm Res 9:1587-1591 (1992).
29. Fielding R, Smith P, Wang L, PorterJ, Guo L.
Comparative pharmacokinetics of ampho-
tericin B after administration of a novel col-
loidal delivery system, ABCB, and a conven-
tional formulation to rats. Antimicrob Agents
Chemother 35:1208-1213 (1991).
30. Ben-Zvi Z, Hreash F, Kaplanski J. Disposition
of hexobarbitone and antipyrine in DOCA-
hypertensive rats. J Pharm Pharmacol
43:349-352 (1991).
31. Shobha J, Raghuram T. Antipyrine kinetics in
undernourished diabetics. Eur J Clin
Pharmacol 41:359-361 (1991).
32. Belpaire F, DeSmet F, Vyackier L, Vermeulen
A. Rosseel M, Bogaert M, Chauvelot-Moachan
L. Effect of aging on the pharmacokinetics of
atenolol, metoprolol and propranolol in the
rat. J Pharmacol Exp Ther 254:116-122
(1990).
33. Mandema J, Heijligers-Feijen C, Tukker E,
DeBoer A, Danhof M. Modeling of the effect
site equilibration kinetics and pharmacody-
namics ofracemic baclofen and its enantiomers
using quantitative EEG effect measures. J
Pharmacol Exp Ther 261:88-94 (1992).
34. Wuis E, Dirks M, Termond E, Vree T,
Vanderkleijn E. Plasma and urinary excretion
kinetics of oral baclofen in healthy subjects.
EurJ Clin Pharmacol 37:181-184 (1989).
35. KuriharaA, Naganuma H, Hisaoka M, Tokiwn
H, Kawaharia G. Prediction ofhuman pharma-
cokinetics of panipenem-betamipron, a new
carbopenem from animal data. Antimicrob
Agents Chemother 36:1810-1815 (1992).
36. Bonati M, Latini R, Tognoni G, Young J,
Garattini S. Interspecies comparison of in vivo
caffeine pharmacokinetics in man, monkey,
rabbit, rat and mouse. Drug Metab Rev
15:1355-1383 (1984-85).
37. Turner P, Renton K. The interaction between
carbamazepine and erythromycin. Can J
Physiol Pharmacol 67:582-586 (1989).
38. Garcia-Carborell M, Granero L, Torres-
Molina F, Aristorena J, Peris-Ribera E.
Nonlinear pharmacokinetics of cefadroxil in
the rat. Drug Metab Dispos 21:215-217
(1993).
39. Sawada Y, Hanano M, Sugivama Y, Iga T.
Prediction of the disposition of b-lactam
antibiotics in humans from pharmacokinetic
parameters in animals. J Pharmacokinet
Biopharm 12:241-261. (1984).
40. Matsushita H, Suzuki H, Sugiyama Y, Sawada
Y, Iga T, Hanano M, Kawaguchi Y. Prediction
of the pharmacokinetics of cefodizime and
cefotetan in humans from their pharmacoki-
netic parameters in animals. J Pharmacobio-
Dyn 13:602-611 (1990).
41. Korting H, Schafer-Korting M, Maass L,
Kiesel N, Mutschler E. Cefodizime in serum
and skin blister fluid after single intravenous
and intramuscular doses in healthy volunteers.
Antimicrob Agents Chemother 31:1822-1825
(1987).
42. Isert D, KIesel N, Limbert M, Markus A,
Seibert G, Schrinner E. Pharmacokinetics of
cefpirone administered intravenously or intra-
muscularly to rats and dogs. J Antimicrob
Chemother 29:31-37 (1992).
43. Kavi J, Andrews J, Ashby J, Hillman G, Wise
R Pharmacokinetics and tissue penetration of
cefpirome, a new cephalosporin. J Antimicrob
Chemother 22:911-916 (1988).
44. Mordenti J. Pharmacokinetic scale-up:accurate
prediction of human pharmacokinetic profiles
from animal data. J Pharm Sci 74:1098
(1995).
45. Nakashima E, Matshushita R, Takeaki M,
Nakanishi T, Ichimura F. Comparative phar-
macokinetics of cefoperazone and cephradine
in untreated streptozotocin diabetic rats. Drug
Metab Dispos 20:730-735 (1992).
46. Pettijohn F, Potter P, Siever R. Relation
between binding to plasma protein, apparent
volume of distribution and rate constants of
disposition and elimination for chlorpromazine
in three species. J Pharm Pharmacol
24:818-819 (1972).
47. Gomita Y, Eto K, Furuno K, Araki Y. Effects
of exposure to standard-and-nicotine-reduced
cigarette smoke on pharmacokinetics of theo-
phylline and cimetidine in rats. J Pharm Sci
81:1132-1135 (1992).
48. Litterst C, Magin R. Alterations in plasma
pharmacokinetics ofcisplatin in tumor-bearing
rats. Cancer Chemother Pharmacol 22:1-4
(1988).
49. Woodnutt G, Kernutt I, Mizen L, Mizen L.
Pharmacokinetics and distribution of ticar-
cillin-clauvlanic acid (Timentin) in experimen-
tal animals. Antimicrob Agents Chemother
31:1826-1830 (1987).
50. Boni J, Barr W, Martin B. Cocaine inhalation
in the rat:pharmacokinetics and cardiovascular
response. J Pharmacol Exp Ther 257:307-315
(1991).
51. Boxenbaum H. Interspecies scaling, allometry,
physiological time and the ground plan of
pharmacokinetics. J Pharmacokin Biopharm
10:206-213 (1982).
52. Sangalli L, Bartolotti, Jiritano L, Bonati M.
Cyclosporine pharmacokinetics in rats and
interspecies comparison in dogs, rabbits, rats
and humans. Drug Metab Dispos 16:749-753
(1988).
53. Igari Y, Sugiyama Y, Sawada Y, Iga T, Hanano
M. In vitro and in vivo assessment of hepatic
and extra-hepatic metabolism of diazepam in
the rat. J Pharm Sci 73:825-828 (1984).
54. Lin J, Hooke K, Yeh K, Duggan D. Dose-
dependent pharmacokinetics of difllunisal in
rats:dual effects ofprotein binding and metab-
olism. J Pharmacol Exp Ther 235:402-406
(1985).
55. Harrison L, Gibaldi M. Pharmacokinetics of
digoxin in the rat. Drug Metab Dispos
4:88-93 (1976).
56. Tsunekawa Y, Hasegawa T, Nadai M, Takagi
K, Nabeshima T. Interspecies differences and
scaling for the pharmacokinetics of xanthine
derivatives. J Pharm Pharmacol 44:594-599
(1992).
57. Kinoshita H, Ohishi N, Kato M, Tokura S,
Okazaki A. Pharmacokinetics and distribution
of recombinant erythropoietin in rats.
Arzneim-Forsch 42:174-178 (1992).
58. Salmonson T, Danielson B, Wikstrom B. The
pharmacokinetics of recombinant human ery-
thropoietin after intravenous and subcutaneous
administration to healthy subjects. Br J Clin
Pharmacol 29:709-713 (1990).
59. DaSilva V, McLean A. Effect of two different
types ofmalnutrition on the rate ofelimination
of ethanol in rats. Biocheml Pharmacol
37:4235-4238 (1988).
60. Bachmann K, Jahn D, Yang C, Schwartz J.
Ethosuximide disposition kinetics in rats.
Xenobiotica 18:373-380 (1988).
61. Chien D, Sandri R, Tang-Liu D. Systemic
pharmacokinetics of acitretin, etretinate,
isotretinoin and acetylenic retinoids in guinea
EnvironmentalHealth Perspectives * Volume 104, Number4, April 1996 405Articles - Bachmann et al.
pigs and obese rats. Drug Metab Dispos
20:211-217 (1992).
62. Larsen F, Jakobsen P, Larsen C. Norgaard A,
Kragballe K, Nielsen-Kudsk F. Single dose
pharmacokinetics of etretin and etretinate in
psoriatic patients. Pharmacol Toxicol
61:85-88 (1987).
63. Lin JH, Los L, Ulm E, Duggan P. Urinary
excretion kinetics of famotidine in rats. Drug
Metab Dispos 15:212-215 (1987).
64. Adusumalli V, Yang J, Wong K, Kucharczyk
N, Sofia R Felbamate Pharmacokinetics in the
rat, rabbit and dog. Drug Metab Dispos
19:1116-1125 (1991).
65. Graves N, Ludden T, Holmes G, et al.
Pharmacokinetics of felbamate, a novel
antiepileptic drug:Application of mixed-effect
modeling to clinical trials. Pharmacotherapy
9:372-376 (1989).
66. Hug CJr, Murphy M. Tissue redistribution of
fentanyl and termination of its effects in rats.
Anesthesiology 55:369-375 (1981).
67. Caccia S, Cappi M, Fracasso C, Garattini S.
Influence of dose and route of administration
on the kinetics offluoxetine and its metabolite
norfluoxetine in the rat. Psychopharmacology
100:509-514 (1990).
68. Berry B, Jamali F. Enantiomeric interaction of
flurbiprofen in the rat. J Pharm Sci
78:632-634 (1989).
69. Kean W, Antal E, Grace E, Cauvier H,
RischkeJ, Buchanan W. The pharmacokinetics
offlurbiprofen in younger and elderly patients
with rheumatoid arthritis. J Clin Pharmacol
32:41-48 (1992).
70. Engineer M, Bodley G Sr, Newman R, W-Ho
D. Effects of cisplatin-induced nephrotoxicity
on gentamicin pharmacokinetics in rats. Drug
Metab Dispos 15:329-334 (1987).
71. Shah A, Jung D. Dose-dependent pharmacoki-
netics of ibuprofen in the rat. Drug Metab
Dispos 15:151-154 (1987).
72. SawadaY, Hanano M, SugivamaY, Harashima
H, Iga T. Prediction ofthe volumes ofdistrib-
ution of basic drugs in human based on data
from animals. J Pharmacokinet Biopharm
12:587-596 (1984).
73. Ogiso T, Ito Y, Iwaki M, Atago H. A pharma-
cokinetic model for the percutaneous absorp-
tion of indomethacin and the prediction of
drug disposition kinetics. J Pharm Sci
78:319-323. (1989).
74. Zeruesenay D, Siegmund W, Zschiesche M,
Franke G, Walter R, Bleyer H. Pharmaco-
kinetic interactions between isoniazid and
theophylline in rats. J Pharm Pharmacol
44:893-897 (1992).
75. Chien D, Sandri R, Tang-Liu D. Systemic
pharmacokinetics of acitretin, etretinate,
isotretinoin and acetylenic retinoids in guinea
pigs and obese rats. Drug Metab Dispos
20:211-217 (1992).
76. Remmel R, Amoh K, Abdel-Monem M. The
disposition and pharmacokinetics ofketocona-
zole in the rat. Drug Metab Dispos
15:735-739 (1987).
77. Foster R, Jamali F. Stereoselective pharmacoki-
netics of ketoprofen in the rat. Drug Metab
Dispos 16:623-626. (1988).
78. Mroszczak E, Lee F, Combs D, Sarquist F,
Huang B, Wu A, Tokes L, Maddox M, Cho
D. Ketorolac, tromethamine absorption, distri-
bution, metabolism, excretion and pharmaco-
kinetics in animals and humans. Drug Metab
Dispos 15:618-626 (1987).
79. Fruncillo R, Digregorio G. Pharmacokinetics
ofpentobarbital, quinidine, lidocain and theo-
phylline in the thermally injured rat. J Pharm
Sci 73:1117-1121 (1984).
80. Bredberg U, Paalzow L. Pharmacokinetics of
methysergide and its metabolite methyler-
gometrine in the rat. Drug Metab Dispos
18:338-343 (1990).
81. Bredberg U, Eyjolfsdottir, Paalow L, Tfelt-
Hansen V, Tfelt-Hanson V. Pharmacokinetics
of methysergide and its metabolite methyl-
ergometrine in man. Eur J Clin Pharmacol
30:75-77 (1986).
82. Ling G, Umans J, Inturrisio C. Radio
immunoassay and pharmacokinetics in the rat.
J Pharmacol Exp Ther 217:147-151 (1981).
83. Bakke 0, Segura J. The absorption and elimi-
nation of metoclopramide in three animal
species. J Pharm Pharmacol 28:32-39 (1976).
84. Aarons L, Mandema J, Danhof M. A popula-
tion analysis ofthe pharmacokinetics and phar-
macodynamics of midazolam in the rat. J of
Pharmacokin Biopharm 19:485-496 (1991).
85. Bhargava H, Villar V. Pharmacodynamics and
pharmacokinetics of intravenously adminis-
tered morphine in spontaneously hypertensive
and normotensive Wistar-Kyoto rats. J
Pharmacol Exp Ther 261:290-296 (1992).
86. Higuchi S, Shiobana Y. Comparative pharma-
cokinetics ofnicardipine hydrochloride, a new
vasodilator in various species. Xenobiotica
10:447-454 (1980).
87. Kveremater G, Taylor L, DeBethizv J, Vessel
E. Pharmacokinetics of nicotine and 12
metabolites in the rat. Application of a new
radiometric high performance liquid chro-
matographic assay. Drug Metab Dispos
16:125-129 (1988).
88. Okezaki E, Terasaki T, Nakamura M, Nagata
0, Kato H, Tsuji A. Structure-tissue distribu-
tion relationship based on physiological phar-
macokinetics for NY-198, a new antimicrobial
agent, and the related pyridonecarboxylic acids.
DrugMetab Dispos 16:865-874 (1988).
89. Lode H, Hoffken G, Prinzing C, Glatzel P,
Wiley R, Olschewski P, Sievers B, Reimnitz D,
Borner K, Koeppe P. Comparative pharmaco-
kinetics of new quinolones. Drugs 34(suppl
1):21-25 (1987).
90. Ichimura F, Yokoyawa K, Yamana T, Tsuji A,
Mizukami Y. Physiologic pharmacokinetic
model for pentazocin, I. tissue distribution and
elimination in the rat. IntJ Pharm 15:321-333
(1983).
91. Said S, Foda A. Influence ofcimetidine on the
pharmacokinetics ofpiroxicam in rat and man.
Arzneim-Forsch 39:790-792 (1989).
92. NicolsA, D'Ambrosio R, Pyszczynski N, Jusko
W. Pharmacokinetics and pharmacodynamics
ofprednisolone in obese rats. J Pharmacol Exp
Ther 250:963-970 (1989).
93. Huang M, Jusko W. Nonlinear pharmacoki-
netics and interconversion ofprednisolone and
prednisone in rats. J Pharmacokinet Biopharm
18:401-421 (1990).
94. Basseches P, DiGregorio G. Pharmacokinetics
ofprocainamide in rats with extra-hepatic bil-
iary obstruction. J Pharm Sci 71:1256-1259
(1982).
95. Puigdemont A, Guitart R, DeMora F, Arboix
M. Prediction of the disposition of
propafenone in humans and dogs from phar-
macokinetic parameters in other animal
species. J Pharm Sci 80:1106-1109 (1991).
96. Evans G, Nies A, Shand D. The disposition of
propranolol III. Decreased half-life and volume
ofdistribution as a result ofplasma binding in
man, monkey, dog and rat. J Pharmacol Exp
Ther 186:114-122 (1973).
97. Mihaly G, Date N, VeeNendaal J, Newman K,
Smallwood R. Decreased hepatic elimination
of pyrimethamine during malaria infection.
Biochemical Pharmacol 36:2827-2829 (1987).
98. Harashima H, Sawada, Sugiyama Y, Iga T,
Hanano M. Analysis ofnon-linear tissue distri-
bution of quinidine in rats by physiologically
based pharmacokinetics. J Pharmacokinet
Biopharm 13:425-440 (1985).
99. Yih T, Van Rossum, J. Pharmacokinetics of
some homologous series of barbituates in the
intact rat and in the isolated perfused rat liver.
J Pharmacol Exp Ther 203:184-202 (1977).
100.Breimer D. Clinical pharmacokinetics of hyp-
notics. Clin Pharmacokinet 2:93-109 (1977).
101.Tremaine L, Welch W, Ronfeld R.
Metabolism and disposition of the 5-hydrox-
ytryptamine uptake blocker sertraline in the rat
and dog. Drug Metab Dispos 17:542-550
(1989).
102.DeVane C. Pharmacokinetics of the selective
serotonin reuptake inhibitors. J Clin Psychiatry
53:2(suppl) 13-19 (1992).
103.Kaul S, Ritschel W. Quantitative structure-
pharmacokinetic relationship ofa series ofsul-
fonamides in the rat. Eur J Drug Metab
Pharmacokinet 15:211-217 (1990).
104.Sabater J, Domenech J, Obach R.
Pharmacokinetic study of tolmetin in the rat.
Arzneim-Forsch 42:950-953 (1992).
105.Tu Y, Allen L, Fiorica V, Albers D.
Pharmacokinetics oftrimethoprim in the rat. J
Pharm Sci 78:556-560 (1989).
106.Engineer M, Ho D, Bodey G. Comparison of
vancomycin disposition in rats with normal
and abnormal renal function. Antimicrob
Agents Chemother 20:718-722 (1981).
107.Galinsky R, Levy G. Dose and time-dependent
elimination ofacetaminophen in rats: pharma-
cokinetic implications ofcosubstrate depletion.
J Pharmacol Exp Ther 219:14-20 (1981).
108.Brigden D, Whiteman P. The clinical pharma-
cology of acyclovir and its prodrugs. Scand J
Infect Dis 47:(suppl)33-39 (1985).
109.Tanswell P, Heinzel G, Greischel A, Krause J.
Nonlinear pharmacokinetics of tissue-type
plasminogen activator in three animal species
and isolated perfused rat liver. J Pharmacol Exp
Ther 255:318-324 (1990).
110.Roberts R, Grice J, Wood L, Petroff V,
McGuffie C. Cimetidine impairs the elimina-
tion of theophylline and antipyrine.
Gastroenterology 81:19-21 (1981).
111.Adedoyin A, Aarons L, Houston J. Dose-
dependent pharmacokinetics of cimetidine in
the rat. Xenobiotica 17:595-604 (1987).
112.Bjorkman S, Stanski D, Verotta D, Harashima
H. Comparative tissue concentration profiles
offentanyl and alfentanil in humans predicted
from tissue/blood partitition data obtained in
rats. Anesthesiology. 72:865-873 (1990).
113.Taylor I, Ioannides C, Sacra P, TurnerJ, Parke
D. Effect of deuteration of imipramine on its
pharmacokinetic properties in the rat. Biochem
Pharmacol 32:641-647 (1983).
114.Guissou P, Cuisinaud G, Legheand J, Sassard
J. Chronopharmacokinetics ofindomethacin in
rats. Arzneim-Forsch 37:1034-1037 (1987).
406 Volume 104, Number4, April1996 * EnvironmentalHealth PerspectivesArticles - Scaling basic toxicokinetic parameters
115.Vermeulen A, Belpaire F, DeSmet F,
Vercruysse I, Boggaert M. Aging and the phar-
macokinetics and metabolism of metoprolol
enantiomers in the rat. J Gerontol Biol Sci
48:B108-B114 (1993).
116.Miyamoto Y, Ozaki M, Yamamoto H. Effects,
of adrenalectomy on pharmacokinetics and
antinociceptive activity of morphine in rats.
JpnJ Pharmacol 46:379-386 (1988).
117.Hussey E, Donn K, Daniel M, Hall S, Harker
A, Evans G. Interspecies scaling and pharmaco-
kinetic parameters of 3TC in humans. J Clin
Pharmacol 34:975-977 (1994).
118.Tanaka H, Kaneko T. Pharmacokinetics of
recombinant human granulocyte colony-stimu-
lating factor in the rat. Single and multiple
dosing studies. Drug Metab Dispos
19:200-204 (1991).
119.Drug facts and comparisons. St. Louis,
MO:Facts and Comparisons, Inc.,1995.
120.Merck and Company. Clinical investigator's
confidential informational brochure. MK-0476
summary ofinformation. Rahway, NJ, 1994.
121. Baggot J. Application ofinterspecies scaling to
the bispyridinium oxime HI-6. Am J Vet Res
55:689-691 (1994).
122.Hollinger B, Pastoor T. Case management and
plasma half-life in a case of brodifacoum poi-
soning. Arch Intern Med 153:1925-1928
(1993).
123.Bachmann K, Sullivan T. Dispositional and
Pharmacodynamic characteristics of brodifa-
coum in warfarin-sensitive rats. Pharmacology
27:281-288 (1983).
124.Shah J, Mason W. A dose-ranging study ofthe
pharmacokinetics ofcodeine phosphate follow-
ing intravenous administration to rats. J Pharm
Sci 80:229-231 (1991).
125.Sanders S, Buchi K, Goddard M, Lang J,
Tolman K. Single-dose pharmacokinetics and
tolerance of a cholesteryl sulfate complex of
amphotericin B administered to healthy volun-
teers. Antimicrob Agents Chemother
35:1029-1034 (1991).
126.Ibrahim S, Boudinot F. Pharmacokinetics and
2', 3'-dideoxycytidine after high-dose adminis-
tration to rats. J Pharm Sci 80:36-38 (1991).
127.Ibrahim S, Boudinot F. Pharmacokinetics and
2', 3'-dideoxycytidine in rats: application to
interspecies scale-up. J Pharm Pharmacol
41:829-834 (1988).
128.Borga 0, Andersson K, Edholm L, Fagerstrom
P, Lunell E, Persson C. Enprofylline genetics
in healthy subjects after single doses. Clin
Pharmacol Ther 34:799-804 (1983).
129.Bachmann K, Chu C, Greear V. In vivo evi-
dence that ethosuximide is a cytochrome
P450IIIA substrate. Pharmacology 45:
121-128 (1992).
130. Bachmann K, Schwartz J, Sullivan T, Jauregui
L. Single sample estimate of ethosuximide
clearance. Int J Clin Pharmacol Ther Toxicol
24:546-550 (1986).
131.Groeseneken D, Veulemans H, Masschelein R,
Van Vlem E. Comparative urinary excretion of
ethoxyacetic acid in man and rat after single
low doses of ethylene glycol monoethyl ether.
Toxicol Lett 41:57-68 (1988).
132.Jezequel S. Fluconazole:Interspecies scaling and
allometric relationships of pharmacokinetic
properties. J Pharm Pharmacol 46:196-199
(1993).
133.Vollmer K, von Hodenberg A, K6lle E.
Pharmacokinetics and metabolism of
gabapentin in rat, dog and man. Arzneim-
Forsch 36:830-838 (1986).
134.Van der GraaffM, Vermeulen N, Breimer D.
Disposition of hexobarbital:15 years of an
intriguing model substrate. Drug Metab Rev
19:109-164 (1988).
135.Wood A, Goodwin G, DeSouza R, Green A.
The pharmacokinetic profile of lithium in rat
and mouse. An important factor in psy-
chopharmacological investigation of the drug.
Neuropharmacol 25:1285-1288 (1986).
136.Dickinson R, Baker P, Franklin M, Hooper
W. Facile hydrolysis of meberine in vitro and
in vivo:Negligible circulating concentrations of
the drug after oral administration. J Pharm Sci
80:952-957 (1991).
137.Farris F, Dedrick R, Allen P, Smith C.
Physiological model for the pharmacokinetics
of methylmercury in the growing rat. Toxicol
Appl Pharmacol 119:74-90 (1993).
138.SmithJ, Allen P, Turner M, Most B, Fisher H,
Hall L. The kinetics ofintravenously adminis-
tered methylmercury in man. Toxicol Appl
Pharmacol 128:251-256 (1994).
139.Malviya V, YoungJ, Boike G, Gove N, Deppe
G. Pharmacokinetics of mitomycin-C in plas-
ma and tumor tissue ofcervical cancer patients
and in selected tissues of female rats. Gynecol
Oncol 25:160-170 (1986).
140.Yuan J, Goehl T, Hong L, Clark J, Murrill E,
Moore R. Toxicokinetics of oxazepam in rats
and mice. J Pharm Sci 83:1373-1379 (1994).
141.Bernard E, Donnely H, Maher M, Armstrong
D. Use ofa new bioassay to study pentamidine
pharmacokinetics. J Infect Dis 152:750-754
(1985).
142.Trenk D, Jahnchen E. Effect ofserum protein
binding on pharmacokinetics and anticoagu-
lant activity of phenprocoumon in rats. J
Pharmacokinect Biopharm 8:177-191 (1980).
143.Haustein K, Huller G. Pharmacokinetics of
phenprocoumon. Int J Clin Pharmacol Ther
32:192-197 (1994).
144.Somani S, Khalique A. Pharmacokinetics and
pharmacodynamics ofphysostigmine in the rat
after intravenous administration. Drug Metab
Dispos 15:627-633 (1987).
145.Johansson M, Nordberg A. Pharmacokinetic
studies of cholinesterase inhibitors. Acta
Neurol Scand 149:522-525 (1993).
146.Gasc6n A, Calvo B, Hernandez R,
Dominguez-Gil A, Pedraz J. Interspecies scal-
ing ofcimetidine-theophylline pharmacokinet-
ic interaction: interspecies scaling in pharmaco-
kinetic interactions. Pharm Res 11:945-950
(1994).
147.Manitpisitkul P, Chiou W. Intravenous vera-
pamil kinetics in rats. Marked arteriovenous
concentration difference and comparison with
humans. Biopharm Drug Dispos 14:555-566
(1993).
148.Takada K, Levy G. Comparative pharmacoki-
netics ofcoumarin anticoagulants XLIV. Dose
dependent pharmacokinetics of warfarin in
rats. J Pharm Sci 69:9-14 (1980).
CAAT I1ecogniVion Awara
The Johns Hopkins Center for Alternatives to Animal Testing (CAAT) would like to honor an individual or organization who
has made an outstanding contribution to the field of M5s alternatives and in vitro sciences. We invite the readers ofthis
journal to submit nominations. The award will be presented at the second World Congress on Alternatives and Animal
Use in the Life Sciences, to be held in October 1996 in Utrecht, The Netherlands. Deadline for receipt of nominations is
June 1, 1996. Please send your nomination, including a one-page description ofwhy this individual or organization should
be recognized. Please include a curriculum vitae for individual nominees and a fact sheet or supporting documents for
organizations. A subcommittee ofthe CAAT Advisory board will review the nominations and select the recipient ofthe
CAAT Recognition Award.
Forward nominations to: Alan M. Goldberg, PhD., Johns Hopkins Center for Alternatives to Animal Testing
111 Market Place, Suite &40, baltimore, MP 21202-6709
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